Hyloris Developmentsen Sa Total Liabilities
Hyloris Developmentsen Sa total liabilities. Based on the latest financial reports, Hyloris Developmentsen Sa (HYL) has total liabilities worth €8.16 Million EUR (≈ $9.54 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Hyloris Developmentsen Sa to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hyloris Developmentsen Sa (2016–2024)
Total liabilities of Hyloris Developmentsen Sa from 2016 to 2024. This chart illustrates how Hyloris Developmentsen Sa's total liabilities have evolved over time, based on quarterly financial data.
Hyloris Developmentsen Sa Competitors by Total Liabilities
The table below lists competitors of Hyloris Developmentsen Sa ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trio-Tech International
NYSE MKT:TRT
|
USA | $13.99 Million |
|
Caisse Regionale De Credit Agricole Mutuel Sud Rhone Alpes
PA:CRSU
|
France | €24.15 Billion |
|
Silk Logistics Holdings Ltd
AU:SLH
|
Australia | AU$479.39 Million |
|
BINEX Co. Ltd
KQ:053030
|
Korea | ₩117.14 Billion |
|
Mitrabara Adiperdana PT
JK:MBAP
|
Indonesia | Rp54.08 Million |
|
LiveWire Group Inc.
NYSE:LVWR
|
USA | $99.31 Million |
|
Nykode Therapeutics ASA
OL:NYKD
|
Norway | Nkr5.73 Million |
|
Pioneer Floating Rate Trust
NYSE:PHD
|
USA | $66.83 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Hyloris Developmentsen Sa's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hyloris Developmentsen Sa total assets.
Liquidity & Leverage Metrics
Hyloris Developmentsen Sa Total Liabilities Ratios Explained
Hyloris Developmentsen Sa total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hyloris Developmentsen Sa's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hyloris Developmentsen Sa (2016–2024)
The table below shows the annual total liabilities of Hyloris Developmentsen Sa from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €9.19 Million ≈ $10.75 Million |
+6.73% |
| 2023-12-31 | €8.61 Million ≈ $10.07 Million |
+26.29% |
| 2022-12-31 | €6.82 Million ≈ $7.97 Million |
-55.69% |
| 2021-12-31 | €15.39 Million ≈ $17.99 Million |
+52.01% |
| 2020-12-31 | €10.12 Million ≈ $11.83 Million |
-37.40% |
| 2019-12-31 | €16.17 Million ≈ $18.91 Million |
+30.31% |
| 2018-12-31 | €12.41 Million ≈ $14.51 Million |
+43.45% |
| 2017-12-31 | €8.65 Million ≈ $10.11 Million |
+144.86% |
| 2016-12-31 | €3.53 Million ≈ $4.13 Million |
-- |
About Hyloris Developmentsen Sa
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more